Epacadostat/Durvalumab Combo Well Tolerated in Solid Tumor Trial

At AACR 2018 AACR, Dr. Aung Naing of MD Anderson presented ECHO-203, the first data on epacadostat in combination with an anti –PD-L1 inhibitor.

Source: CancerNetwork - April 17, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Conferences/AACR Street Team Lung Cancer Melanoma News Source Type: news